Trending...
- EDCAPIT Founder Oleh Podobied and Jenny Li Discuss the Future of EdTech in Silicon Valley - 126
- BUY CALIFORNIAN: Governor Newsom launches new campaign to help consumers identify California-made products - 119
- California: Governor Newsom statement on compromise to address wildfire risk, support fire survivors, and create stronger accountability - 118
New preclinical research reports that HuMOLYTE®, a magnesium-containing medical food with 2′-fucosyllactose, reduced chemotherapy-induced gastrointestinal and oral mucosal injury in Wistar rats
SACRAMENTO, Calif. - Californer -- IGH Naturals announced that a peer-reviewed original research study evaluating HuMOLYTE® has been accepted and published in Frontiers in Nutrition. The study, titled "Supplementation with 2′-fucosyllactose, a prebiotic human milk oligosaccharide (HMO), in a magnesium-containing medical food reduces chemotherapy-induced mucositis in Wistar rats," reports preclinical findings on HuMOLYTE®, a medical food formulated with 2′-fucosyllactose, magnesium, sodium, and potassium.
Chemotherapy-induced mucositis is a common and difficult side effect of cancer treatment that can affect the mouth and gastrointestinal tract. It may contribute to painful oral symptoms, diarrhea, dehydration, electrolyte loss, poor nutrition, and interruptions in treatment. For patients and caregivers, these complications can add physical and emotional strain during an already challenging time.
More on The Californer
The newly published study evaluated HuMOLYTE® in Wistar rats exposed to commonly used chemotherapy agents, including doxorubicin, irinotecan, 5-fluorouracil, and cisplatin. According to the publication, HuMOLYTE® supplementation was associated with reduced severity of chemotherapy-induced diarrhea, less chemotherapy-associated weight loss, and preservation of gastrointestinal mucosal structure, including goblet cells.
The study also reported reduced inflammation in ileal, colonic, and oral mucosal tissue among animals supplemented with HuMOLYTE®. In laboratory cell studies, HuMOLYTE® improved goblet cell survival, supported mucin secretion, and helped maintain epithelial barrier function.
"This publication marks an important milestone for IGH Naturals and HuMOLYTE®," said Dr. Sourabh Kharait, corresponding author of the study. "While these findings are preclinical and require confirmation in human clinical trials, they provide a strong scientific foundation for further investigation of HuMOLYTE® as a supportive nutrition strategy for chemotherapy-related mucositis."
More on The Californer
The authors noted that chemotherapy-induced mucositis remains an area of high unmet need, with few consistently effective preventive therapies available. The study concluded that an oral rehydration mix containing 2′-fucosyllactose HMO and electrolytes may have potential as a food-grade approach to supporting oral hydration and electrolyte repletion during chemotherapy.
IGH Naturals emphasizes that the findings are based on animal and in vitro studies. HuMOLYTE® is not intended to diagnose, treat, cure, or prevent disease. Patients should speak with their oncology care team before adding any medical food or nutrition product during cancer treatment.
IGH Naturals is a nutrition-focused company developing science-backed medical foods and supportive nutrition products for people facing complex health challenges. HuMOLYTE® is the company's medical food formulated to support hydration and electrolyte repletion with 2′-fucosyllactose, magnesium, sodium, and potassium.
Chemotherapy-induced mucositis is a common and difficult side effect of cancer treatment that can affect the mouth and gastrointestinal tract. It may contribute to painful oral symptoms, diarrhea, dehydration, electrolyte loss, poor nutrition, and interruptions in treatment. For patients and caregivers, these complications can add physical and emotional strain during an already challenging time.
More on The Californer
- California's public safety strategy works: Governor Newsom's commitment helps lower crime as new study shows violence prevention saves lives
- Dividend Stacker Launches Free Calendar and Alerts for High-Yield ETF Payouts
- California: Six years after Creek Fire, Governor Newsom recognizes historic nighttime CalGuard rescue that saved 242 lives
- Paul Ohana - From Beverly Hills Salon Chair To Beauty Founder Celebrity Hair Expert
- MSI Tax, Accounting and Finance Outlines Tax Preparation Ahead of October 15 Extension Deadline
The newly published study evaluated HuMOLYTE® in Wistar rats exposed to commonly used chemotherapy agents, including doxorubicin, irinotecan, 5-fluorouracil, and cisplatin. According to the publication, HuMOLYTE® supplementation was associated with reduced severity of chemotherapy-induced diarrhea, less chemotherapy-associated weight loss, and preservation of gastrointestinal mucosal structure, including goblet cells.
The study also reported reduced inflammation in ileal, colonic, and oral mucosal tissue among animals supplemented with HuMOLYTE®. In laboratory cell studies, HuMOLYTE® improved goblet cell survival, supported mucin secretion, and helped maintain epithelial barrier function.
"This publication marks an important milestone for IGH Naturals and HuMOLYTE®," said Dr. Sourabh Kharait, corresponding author of the study. "While these findings are preclinical and require confirmation in human clinical trials, they provide a strong scientific foundation for further investigation of HuMOLYTE® as a supportive nutrition strategy for chemotherapy-related mucositis."
More on The Californer
- ChargeOn Announces Conversational Payment Management Solution
- California and the Australian state of Queensland ink new partnership to accelerate climate resilience, agricultural technology, and innovation
- TitleChain Foundation Opens Sovereign AI & Digital Asset Commons, Invites Builders
- King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence
- California: Governor, First Partner statement on the passing of Gloria Steinem
The authors noted that chemotherapy-induced mucositis remains an area of high unmet need, with few consistently effective preventive therapies available. The study concluded that an oral rehydration mix containing 2′-fucosyllactose HMO and electrolytes may have potential as a food-grade approach to supporting oral hydration and electrolyte repletion during chemotherapy.
IGH Naturals emphasizes that the findings are based on animal and in vitro studies. HuMOLYTE® is not intended to diagnose, treat, cure, or prevent disease. Patients should speak with their oncology care team before adding any medical food or nutrition product during cancer treatment.
IGH Naturals is a nutrition-focused company developing science-backed medical foods and supportive nutrition products for people facing complex health challenges. HuMOLYTE® is the company's medical food formulated to support hydration and electrolyte repletion with 2′-fucosyllactose, magnesium, sodium, and potassium.
Source: IGH Naturals
0 Comments
Latest on The Californer
- Brévant Guide Launches New National Restaurant Guide Across Canada
- Long Beach: City to Host Annual Second Chance Job & Resource Fair
- Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not
- Waterside Productions Announces Lena Kushnir's New Book "A Gentle Return Back to You"
- Malibu Chili Cook-Off® Announces 2026 Event Partners
- Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing
- VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8
- City of Long Beach Launches Safe & Secure Grant Program to Help Local Businesses Strengthen Storefront Safety
- Volant Announces Major Partnership with the STEM Racing Canada Program to CHAMPION YOUTH ENGINEERING
- For Labor Day…Take a look at a poem about Manufacturing called "It used to be Made in America"
- Governor Newsom announces nearly 15,300 illegal hemp, kratom and 7-OH products removed from California store shelves
- SEEAG receives $40,000 AgWest Farm Credit Grant For Southbank Learning Farm
- California's legal cannabis market generates $8.4 billion for Californians as state cracks down on illicit operators
- California: Governor Newsom announces CalGuard has seized $534 million in deadly fentanyl, helping keep drugs off the streets as crime falls statewide
- Indiewood Film Festival Highlights Phillip E. Walker's Appearances at Fifteen September 2026 Events
- Decisynx Announces Vauryn AI Learning Companion With Global Release Planned for 2026
- Badanamu and Friends Live Brings Hit Animated Series to Stages Across the United States
- 54 Million Contract. New Chapter as AI Cybersecurity Platform Expands, Margins Surge & Management Signals Confidence. Cycurion, Inc: (NAS DAQ: CYCU)
- MommyAndMe.club Expands Parent-Child Class Directory to All 50 States and Washington, D.C
- Work 365 Deepens TD SYNNEX Integration with Automated Azure Billing
